** Shares of transdermal pharma products maker Nutriband
rise ~28% to $6.67
** Brokerage Noble Capital starts coverage on NTRB with "outperform" rating and sets PT at $13
** PT represents a 148% upside to the stock's last
** NTRB is developing Aversa, a proprietary technology that makes transdermal patches safer by preventing abuse and misuse of potent opioids like fentanyl
** Brokerage says NTRB's tech has "abuse-deterrent" features that differentiate it from other transdermal patches on the market
** Also notes NTRB's partnership to add the Aversa technology to Kindeva's transdermal fentanyl patch could be a highly effective means to stop misuse
** NTRB shares doubled in 2024
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。